Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus chemoradiotherapy in locally advanced cervical cancer
2017-003622-33Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in Cervical Cancer (CC) (2 arms), sponsored by Gustave Roussy. Primary endpoint: Progression-free survival. Started Jan 2018; status: active.
02
Drugs
atezolizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2017-003622-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003622-33.